Association of First-In-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma

JAMA Oncology- United States

doi 10.1001/jamaoncol.2017.3462

Full Text

Abstract

Available in

Categories

Cancer Research

Date

January 1, 2018

Authors

Andrew J. Sinnamon

Madalyn G. Neuwirth

Phyllis A. Gimotty

Tara C. Gangadhar

Ravi K. Amaravadi

Lynn M. Schuchter

Giorgos C. Karakousis

Publisher

American Medical Association (AMA)

Related search

Immune Checkpoint Inhibition in Patients With Brain Metastases

Annals of Translational Medicine

English

Recurrent Pneumonitis in Patients With Melanoma Treated With Immune Checkpoint Inhibitors

Cancer Research

English

1210 Enhancing the Therapeutic Efficacy of Immune Checkpoint Inhibition and Targeted Therapy Using Anti-Tumor Antibodies in Mouse Melanoma

Journal of Investigative Dermatology

Molecular Biology

English

Impact of Clinicopathological Characteristics on Survival in Patients Treated With Immune Checkpoint Inhibitors for Metastatic Melanoma

International Journal of Cancer

Cancer Research

English

Immune Checkpoint Inhibitors Therapy in Older Patients (≥ 70 Years) With Metastatic Melanoma: A Multicentre Study

Postepy Dermatologii I Alergologii

English

Does Metastasectomy Improve Survival in Patients With Stage IV Melanoma? A Cancer Registry Analysis of Outcomes

Journal of Surgical Oncology

English

843 Immune Checkpoint Molecule PD-1H/VISTA Expression Correlates With Melanoma Survival

Journal of Investigative Dermatology

Molecular Biology

English

P3.13-10 Factors Associated With Long-Term Survival of Stage IV NSCLC Patients on First-Line EGFR-Targeting Therapy

Journal of Thoracic Oncology

Respiratory Medicine

English

Concurrent Therapy With Immune Checkpoint Inhibitors and TNFα Blockade in Patients With Gastrointestinal Immune-Related Adverse Events

Journal for ImmunoTherapy of Cancer

Molecular Medicine

Cancer Research

English